Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDT AustraliaASX:IDT Days Sales Outstanding is 93.62 as of Jun. 2026, which is 3% below its 10-year median of 96.09. The stock has 5 warning signs investors should review. Among 947 Drug Manufacturers companies, IDT Australia ranks worse than 70.75% on this metric.
IDT Australia's average Accounts Receivable for the
six
months ended in Jun. 2026 was A$5.46 Mil. IDT Australia's Revenue for the
six
months ended in Jun. 2026 was A$10.63 Mil.
Hence, IDT Australia's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 93.62.
The historical rank and industry rank for IDT Australia's Days Sales Outstanding or its related term are showing as below:
ASX:IDT'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.03 Med: 96.09 Max: 146.7
Current: 97.61
During the past 13 years, IDT Australia's highest Days Sales Outstanding was 146.70. The lowest was 51.03. And the median was 96.09.
ASX:IDT's Days Sales Outstanding is ranked worse than 70.75% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs ASX:IDT: 97.61
IDT Australia's Days Sales Outstanding
declined
from Jun. 2025 (137.46) to Jun. 2026 (93.62).
IDT Australia (ASX:IDT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
IDT Australia Days Sales Outstanding Related Terms
IDT Australia Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for IDT Australia's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDT Australia Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IDT Australia's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where IDT Australia's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDT Australia (ASX:IDT) has a Days Sales Outstanding of 93.62 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on IDT Australia and its competitors. This is near median its historical median of 96.09. Over the past decade, IDT Australia's Days Sales Outstanding has ranged from 51.03 to 146.70. According to the industry distribution chart, IDT Australia ranks #670 out of 947 companies in the Drug Manufacturers industry, placing it in the top 70.7%.
Is IDT Australia's Days Sales Outstanding too high?
IDT Australia's current Days Sales Outstanding of 93.62 is near median its 10-year median of 96.09. Over the past 10 years, this metric has ranged from a low of 51.03 to a high of 146.70. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. IDT Australia's value of 93.62 is 30.1% above this industry median. Based on the distribution chart, IDT Australia ranks #670 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does IDT Australia's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, IDT Australia ranks #670 out of 947 companies for Days Sales Outstanding. This places IDT Australia in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. IDT Australia's value of 93.62 is 30.1% above this benchmark. Historically, IDT Australia's own Days Sales Outstanding has ranged from 51.03 to 146.70 over the past decade. While the company's 10-year median is 96.09 vs. the industry median of 71.98, IDT Australia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDT Australia's current Days Sales Outstanding of 93.62 is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on IDT Australia and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDT Australia's current Days Sales Outstanding is 93.62, which is near median its own 10-year median of 96.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.13, compared to a current price of A$0.05 — trading 63.8% below its estimated fair value. The current Days Sales Outstanding is 93.62, which is near median its 10-year median of 96.09 and 30.1% above the Drug Manufacturers industry median of 71.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current Days Sales Outstanding is 93.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDT has been successfully added to your 
